Investago Logo Header
Nathaniel Yeo 747NDboAWNY Unsplash

Acadia and Neuren Ink Global Licensing Deal

Shares in Acadia Pharmaceuticals surged by almost 25% in the latest trading session, finishing at $32.18.*

acadia1

Performance of ACADIA Pharmaceuticals Inc over 5 years. Source: investing.com

This big jump is thanks to an exciting announcement about a deal with Neuren Pharmaceuticals. As part of the deal, Acadia will now be able to sell the drug trofinetide outside of North America. Plus, Acadia has bagged exclusive rights to a drug in development by Neuren, known as NNZ-2591, for the treatment of Rett syndrome and Fragile X syndrome. In return, Neuren will get a $100 million payment upfront, along with the possibility of further payments based on future success. Even though Acadia is expected to report a slight loss of $0.22 per share in its upcoming report, experts are feeling optimistic. They've increased their earnings estimate for the company by 7.7% over the last month, hinting at a possible increase in the share price in the future. On the other hand, Tango Therapeutics, another company in the same industry, saw a slight dip in its share price. It closed at $3.43, which is a 0.6% decrease.*

acadia2

Performance of Tango Therapeutics Inc over 5 years. Source: investing.com

The company's earnings estimate for the upcoming report hasn't changed over the past month and remains at a loss of $0.35 per share.

 

* Past performance is no guarantee of future results

 

Risk Warning: CFDs are complex instruments and come with a high risk of rapid financial loss due to leverage. 71.96% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Shutterstock 2538872661
Summer demand and geopolitical risks are keeping oil at $70 per barrel

Brent crude held around $70 a barrel in mid-July 2025 thanks to strong summer gasoline demand and geopolitical risk in the Red Sea. Near-term sentiment is firm, but medium-term forecasts call for rising inventories and lower prices by year-end. [1]
Shutterstock 2674243129
The Fed has resumed easing: What does the interest rate cut mean for investors?

In September 2025 the U.S. central bank took a step many investors had long hoped for. After months of hesitation it cut interest rates by 25 basis points to a new range of 4.00–4.25 percent. Although the move is relatively small, it signals the start of a new phase of monetary policy that could drive significant shifts of capital across financial markets. How can this be used most effectively?
Shutterstock 2217530197
While Tesla is losing momentum, competitor BYD is excelling

While Tesla’s reputation in Europe is losing its luster, Chinese competitor BYD has moved to the center of investors’ attention. Demand for Tesla’s new models remains below expectations, especially for the Cybertruck, which has struggled this year with reliability issues and safety shortcomings. By contrast, BYD is taking the EV spotlight and overtaking Tesla in global sales.
App 1
Risk Warning: CFDs are complex instruments and come with a high risk of rapid financial loss due to leverage. 71.96% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.